Loading patent…
AssigneeAbbVie Inc.
InventorsRandy R. Robinson, Pooja Hingorani, Edwin Jeng, Jiuhong Zha, Dolonchampa Maji, Kevin M.J. Huang, Laura M. Kreckler
Estimating the term…
The present application pertains to, among other things, improved methods of treating advanced solid tumors, including small cell lung cancer (“SCLC”), relapsed/refractory (R/R) SCLC, high-grade central nervous system (“CNS”) tumors (glioblastoma (“GBM”), IDH-wild-type Grade 4; oligodendroglioma, IDH-mutant, and 1p/19q-codeleted Grade 3; astrocytoma, IDH-mutant Grade 3 or Grade 4), and high-grade neuroendocrine carcinomas/neuroendocrine tumors (“NECs/NETs”), using an anti-SEZ6 antibody drug conjugate (“anti-SEZ6 ADC”). In specific embodiments, the anti-SEZ6 ADC consists of a SEZ6-targeting antibody conjugated to a potent topoisomerase 1 inhibitor (Top1i) payload.
A method of treating a small cell lung cancer (“SCLC”) tumor in a human subject in need thereof or population of human subjects in need thereof, comprising administering intravenously every three weeks to the human subject having said SCLC tumor a therapeutically effective amount of 1.3 mg/kg, 1.5 mg/kg, 1.8 mg/kg, 2.5 mg/kg, 3.0 mg/kg, or 3.5 mg/kg of an anti-SEZ6 antibody drug conjugate (“anti-SEZ6 ADC”) having the following structure:
4-8. (canceled)
10-11. (canceled)
13-41. (canceled)
A method of treating a central nervous system (“CNS”) tumor in a human subject in need thereof or population of human subjects in need thereof, comprising administering intravenously every three weeks to the human subject having said CNS tumor a therapeutically effective amount of 1.3 mg/kg, 1.8 mg/kg, 2.5 mg/kg, 3.0 mg/kg, or 3.5 mg/kg of an anti-SEZ6 antibody drug conjugate (“anti-SEZ6 ADC”) having the following structure:
43-62. (canceled)
A method of treating a high-grade neuroendocrine carcinoma/neuroendocrine tumor (“NEC/NET”) in a human subject in need thereof or population of human subjects in need thereof, comprising administering intravenously every three weeks to the human subject having said NEC/NET tumor a therapeutically effective amount of 1.3 mg/kg, 1.8 mg/kg, 2.5 mg/kg, 3.0 mg/kg, or 3.5 mg/kg of an anti-SEZ6 antibody drug conjugate (“anti-SEZ6 ADC”) having the following structure:
64-83. (canceled)
A method of treating a small cell lung cancer (“SCLC”) tumor in a human subject in need thereof or population of human subjects in need thereof, comprising administering intravenously every three weeks to the human subject having said SCLC tumor a therapeutically effective amount of 1.5 mg/kg or 1.8 mg/kg of an anti-SEZ6 antibody drug conjugate (“anti-SEZ6 ADC”) and an anti-PD-L1 antibody, the anti-SEZ6 ADC having the following structure:
Dependencies are inferred from the claim text.